石药集团(01093)：GLP -1 / GIP受体双偏向性激动多肽注射液(SYH2069注射液)在中国获临床试验批准

智通财经2025-12-29

智通财经APP讯，石药集团(01093)发布公告，集团开发的GLP -1 / GIP受体双偏向性激动多肽注射液( SYH2069注射液 )已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。此前，该产品亦已获得美国食品药品监督管理局(FDA)批准在美国开展临床试验。该产品有望成为中国首款进入临床阶段的 GLP -1 / GIP 受体双偏向激...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2595813917?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-29 18:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595813917","market":"hk","top_or_hot":-1,"title":"石药集团(01093)：GLP -1 / GIP受体双偏向性激动多肽注射液(SYH2069注射液)在中国获临床试验批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，石药集团(01093)发布公告，集团开发的GLP -1 / GIP受体双偏向性激动多肽注射液( SYH2069注射液 )已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。此前，该产品亦已获得美国食品药品监督管理局(FDA)批准在美国开展临床试验。该 产 品 有 望 成 为 中 国 首 款 进 入 临 床 阶 段 的 GLP -1 / GIP 受 体 双 偏 向 激...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1386609.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药集团(01093)：GLP -1 / GIP受体双偏向性激动多肽注射液(SYH2069注射液)在中国获临床试验批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药集团(01093)：GLP -1 / GIP受体双偏向性激动多肽注射液(SYH2069注射液)在中国获临床试验批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-29 18:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1386609.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，石药集团(01093)发布公告，集团开发的GLP -1 / GIP受体双偏向性激动多肽注射液( SYH2069注射液 )已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。此前，该产品亦已获得美国食品药品监督管理局(FDA)批准在美国开展临床试验。该 产 品 有 望 成 为 中 国 首 款 进 入 临 床 阶 段 的 GLP -1 / GIP 受 体 双 偏 向 激...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1386609.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YT58.USD","symbol_name":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1386609.html","article_id":"2595813917","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595813917","pubTimestamp":1767003869,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，石药集团 发布公告，集团开发的GLP -1 / GIP受体双偏向性激动多肽注射液已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。非人灵长类重复给药毒理研究显示，该产品耐受性良好，未观察到任何呕吐及胃肠道不良反应。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1191":"制药","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","BK4144":"石油与天然气的储存和运输","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","BK4590":"PTP","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","BK1515":"抗疫概念","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","GLP":"Global Partners Lp","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1521":"挪威政府全球养老基金持仓","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","01093":"石药集团","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC"},"translate_title":"CSPC Pharmaceutical Group (01093): GLP-1/GIP receptor double-biased agonist peptide injection (SYH2069 injection) was approved for clinical trials in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5,"GLP":1.5},"content_text":"智通财经APP讯，石药集团(01093)发布公告，集团开发的GLP -1 / GIP受体双偏向性激动多肽注射液( SYH2069注射液 )已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。此前，该产品亦已获得美国食品药品监督管理局(FDA)批准在美国开展临床试验。该 产 品 有 望 成 为 中 国 首 款 进 入 临 床 阶 段 的 GLP -1 / GIP 受 体 双 偏 向 激 动 剂 ， 可 选 择 性 激 活 c AMP通路，显著降低b-arrestin募集，从而减少受体内吞及脱敏，提高药效和效果持续性。同时，结合长半衰期修饰平台技术，该产品能实现更深度、更持久的减重效果。在饮食诱导肥胖(DIO)小鼠和非人灵长类的研究中，该产品在减重及代谢改善方面的效果均显著优于同类上市产品。非人灵长类重复给药毒理研究显示，该产品耐受性良好，未观察到任何呕吐及胃肠道不良反应。该产品具备出色的药效及良好的安全性，有望成为超重╱肥胖及其他代谢类疾病的新一代疗法。本 次 获 批 的 临 床 适 应 症 为 肥 胖 或 超 重 合 并 至 少 一 种 体 重 相 关 合 并 症 人 群 的 体 重 管 理 。 此外，该产品亦具备用于改善成人2型糖尿病(T2DM)患者的血糖控制的潜力，具有较高的临床开发价值。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595813917","isCrawlerRequest":true}